2 FTSE 100 world-beating income growth stocks I’d buy to hold forever

These FTSE 100 (INDEXFTSE:UKX) stocks have a track record of creating wealth for investors, that’s why they’re fantastic buy-and-hold investments says this Fool.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

If you’re looking for income stocks to add to your portfolio, then I highly recommend pharmaceutical giant AstraZeneca (LSE: AZN).

Astra’s most attractive quality is the fact that this company is a world leader in the pharmaceutical space, and is currently pushing out some of the most revolutionary treatments for cancer around.

For example, last weekend, the company revealed data at the American Society of Clinical Oncology, showing that its flagship cancer treatment, Imfinzi could prolong the lives of lung cancer patients whose disease had reached the third stage.

On top of this, today, Astra announced that its blood cancer drug, Calquence, showed meaningful improvement in patients with lymphocytic leukaemia when compared with a chemotherapy-based treatment. 

A world-leader

These positive developments only served to reinforce my view that Astra is a giant force in the battle against cancer, and the revolutionary treatment should guarantee an income stream for many years to come. Indeed, after several years of stagnation, City analysts expect the company to return to growth this year.

Analysts have pencilled in normalised earnings per share of $3.60 (283p) for 2019, putting the stock on a forward P/E of 21.2. As the company puts more treatments on the market, analysts are expecting further growth in 2020. The City has pencilled in earnings growth of 19.6% for the year, leaving the stock dealing at a 2020 P/E of 17.8.

This valuation looks a bit on the expensive side, but I think it is a price worth paying for the company’s growth and leading position in the global immuno-oncology market. On top of Astra’s growth potential, investors can also look forward to a dividend yield of 3.6%, covered 1.3 times by earnings per share, that’s before taking into account the City’s earnings growth forecasts for the next two years.

Proven value creator

The second business I’m going to profile has established itself as one of the best property companies UK investors can own over the past few years. The company I’m talking about is FTSE 100 commercial real estate REIT Segro (LSE: SGRO).

Segro owns and manages warehouse properties across the UK and Europe. Demand for these properties has boomed in line with the growing demand for online shopping, and the company has wasted no time in making the most of this opportunity.

Over the past six years, book value per share has increased by around 17% per annum as the enterprise has acquired new properties with reinvested earnings and additional cash from shareholders. And as the portfolio has grown, so has the company’s dividend.

As a REIT, Segro has to distribute the majority of its rental income from warehouse properties to investors as a property income distribution. For 2019, analysts reckon the company will distribute a total of 19.9p to shareholders, giving a dividend yield of 2.8% at the time of writing.

This level of income might not seem that attractive at first, but over the past five years, Segro’s distribution to shareholders has increased by approximately 60%. If the business continues to expand as it has done since 2013, I believe the payout will grow a further 60% over the next five years, potentially giving investors buying today a dividend yield of nearly 6%. This dividend growth potential is the reason why I’m recommending Segro as an income stock you can buy and hold forever.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

2 industry-leading value stocks investors should consider buying

These value stocks are at the top of their respective industries, and look like current bargains with the potential to…

Read more »

Black father and two young daughters dancing at home
Investing Articles

Just released: our 3 top small-cap stocks to buy before August [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

If I’d put £5k in a FTSE 100 index fund 10 years ago, here’s what I’d have now!

Charlie Carman explores the performance of the FTSE 100 index over the past decade and the merits of passive versus…

Read more »

Investing Articles

£15K stashed away? I could turn that into a second income worth £49 a day!

This Fool explains how she would look to gain a second income through investing in UK stocks, and the steps…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

With the Apple share price near an all-time high, would I be crazy to buy more?

After touching all-time highs yesterday, the Apple share price is on a roll. But is there still enough growth ahead…

Read more »

Investing Articles

Nvidia stock has fallen 13% from its 52-week high! What next?

Our writer explains why Nvidia stock has dipped recently and highlights some risks associated with investing in the AI leader…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

The AstraZeneca share price is up 88% in 5 years, but is it just getting started?

The AstraZeneca share price has had a great few years, as acquisitions and clinical trials delighted shareholders. So is there…

Read more »

Investing Articles

Here’s why I’m watching the Anglo American share price

The mining sector has always interested investors. But after a flat few years, I'm wondering what's next for the Anglo…

Read more »